Has Rizwan Romee, MD received payments from drug or device companies?

Yes. Drug and device makers reported $30,853 in general payments to Rizwan Romee, MD across 11 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Rizwan Romee, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Rizwan Romee, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Rizwan Romee, MD

Hematology · Boston, MANPI 1942493101

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (36.3%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by F. Hoffmann-la Roche AG at 37.2% of the total. 2024 is the largest year on record at $15,409, 3.6 times the $4,314 reported in 2021.

$30,853in general payments, 2019–2025

Across 11 payments — averaging $2804.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

F. Hoffmann-la Roche AG$11K
EMD Serono, Inc.$6K
Servier Pharmaceuticals LLC$5K
Sanofi$4K
Sanofi-aventis U.S. LLC$4K
Genentech, Inc.$150
plus $100 from 1 others

What the payments were for

Consulting fees$10,43434%
Speaking & faculty fees$8,68028%
Travel & lodging$11,21036%
Food & beverage$5292%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
F. Hoffmann-la Roche AG	4	$11,489
EMD Serono, Inc.	1	$6,120
Servier Pharmaceuticals LLC	2	$4,760
Sanofi	1	$4,314
Sanofi-aventis U.S. LLC	1	$3,920
Genentech, Inc.	1	$150
Novartis	1	$100

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,853 in reported general payments places this provider in the 75th percentile of 77 hematology providers in Massachusetts.

See all hematology providers in Massachusetts →

Medicare billing

Part B allowed, 2024

$5,153

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology in Boston

Edward BenzBoston$747K
David KuterBoston$543K
Jacalyn RosenblattBoston$455K
Lynn BryBoston$286K
John SloanBoston$257K
Andrew EvensBoston$217K
Omar NadeemBoston$191K
Nathan ConnellBoston$145K
Jean ConnorsBoston$144K
Heather BenjaminBoston$106K

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →